About PRECISIS
Vision
PRECISIS improves the lives of people living with functional brain disorders – through innovative neurostimulation technologies that open new pathways in treatment.
Mission
We continuously improve EASEE® and bring the technology to epilepsy patients across Europe, with the goal of expanding into new markets step by step.
Values
Our values shape the way we collaborate, make decisions, and take responsibility — with physicians and patients at the centre. They unite team spirit, innovation, and entrepreneurial thinking.
Milestones
2015
2019
2021
2022
2023
2024
2025

Our Management

Karl Stoklosa
Managing Director, CEO

Michael Tittelbach
Managing Director, CTO
Our Advisory Board

Dr. Felix Baader

Anthony Bishop

Dr. med. Angela Liedler

André Burch

Peter Weiland

Thorben Katzer
Our Core Values
More about us on LinkedIn
Follow us on LinkedIn for the latest from PRECISIS — clinical updates, milestones, team news, and insights from the world of neurotech and epilepsy care.
Strong Innovations with Strong Funding
News
-
Read more: PRECISIS Named EIB Innovation Champion at TechEU Equity Summit
Published:PRECISIS Named EIB Innovation Champion at TechEU Equity Summit
European Investment Bank recognises PRECISIS for its innovation in neurotechnology and its contribution to advancing new treatment options for drug-resistant focal epilepsy HEIDELBERG, GERMANY, 23 September 2026 – PRECISIS, a German medical technology company developing targeted neuromodulation therapies, has been selected to receive the EIB Innovation Champion Award at the TechEU Equity Summit in Luxembourg.…
-
Read more: FDA Greenlights Pivotal Study of PRECISIS’ Minimally Invasive Brain-Stimulation Therapy for Drug-Resistant Epilepsy

Heidelberg
Published:FDA Greenlights Pivotal Study of PRECISIS’ Minimally Invasive Brain-Stimulation Therapy for Drug-Resistant Epilepsy
PRECISIS, a German neurotechnology company developing minimally invasive brain-stimulation therapies, has received FDA authorization to begin a pivotal clinical trial of its EASEE® system for drug-resistant focal epilepsy – a step that moves the company closer to entering the U.S. market. The pivotal study, following the device’s Breakthrough Designation, will evaluate safety and efficacy in…
